gp130 Cytokines Activate Novel Signaling Pathways and Alter Bone Dissemination in ER+ Breast Cancer Cells.


Journal

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640

Informations de publication

Date de publication:
02 2022
Historique:
revised: 09 08 2021
received: 07 01 2021
accepted: 29 08 2021
pubmed: 4 9 2021
medline: 15 3 2022
entrez: 3 9 2021
Statut: ppublish

Résumé

Breast cancer cells frequently home to the bone marrow, where they encounter signals that promote survival and quiescence or stimulate their proliferation. The interleukin-6 (IL-6) cytokines signal through the co-receptor glycoprotein130 (gp130) and are abundantly secreted within the bone microenvironment. Breast cancer cell expression of leukemia inhibitory factor (LIF) receptor (LIFR)/STAT3 signaling promotes tumor dormancy in the bone, but it is unclear which, if any of the cytokines that signal through LIFR, including LIF, oncostatin M (OSM), and ciliary neurotrophic factor (CNTF), promote tumor dormancy and which signaling pathways are induced. We first confirmed that LIF, OSM, and CNTF and their receptor components were expressed across a panel of breast cancer cell lines, although expression was lower in estrogen receptor-negative (ER

Identifiants

pubmed: 34477239
doi: 10.1002/jbmr.4430
pmc: PMC8828687
mid: NIHMS1737666
doi:

Substances chimiques

Cytokines 0
IL6ST protein, human 0
Interleukin-6 0
Receptors, Cytokine 0
Receptors, OSM-LIF 0
Cytokine Receptor gp130 133483-10-0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

185-201

Subventions

Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : R00CA194198
Pays : United States
Organisme : NIH HHS
ID : P30CA068485
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA068485
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA194198
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA221675
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002243
Pays : United States

Informations de copyright

© 2021 American Society for Bone and Mineral Research (ASBMR).

Références

Sci Rep. 2018 Sep 24;8(1):14299
pubmed: 30250146
Endocr Relat Cancer. 2012 Apr 10;19(2):181-95
pubmed: 22267707
Cancer Cell. 2018 Apr 9;33(4):706-720.e9
pubmed: 29622465
Nat Cell Biol. 2016 Sep 19;18(10):1078-1089
pubmed: 27642788
Nat Rev Cancer. 2016 May 25;16(6):373-86
pubmed: 27220481
J Clin Invest. 2010 Feb;120(2):582-92
pubmed: 20051625
Breast Cancer Res Treat. 2012 Aug;135(1):79-91
pubmed: 22535017
Oncogene. 2020 Feb;39(6):1318-1334
pubmed: 31636389
Breast Cancer Res. 2009;11(1):R7
pubmed: 19187537
Annu Rev Immunol. 1997;15:797-819
pubmed: 9143707
Int J Cancer. 2012 Feb 1;130(3):555-66
pubmed: 21387294
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):210-20
pubmed: 16198159
Structure. 2005 Jun;13(6):861-71
pubmed: 15939018
BMC Bioinformatics. 2011 Dec 15;12:474
pubmed: 22172014
J Cell Physiol. 1990 Oct;145(1):110-9
pubmed: 2170427
Breast Cancer Res Treat. 2015 Apr;150(3):547-57
pubmed: 25820592
Eur J Cancer. 2017 Jul;79:139-148
pubmed: 28494404
Breast Cancer Res Treat. 2001 Mar;66(2):111-21
pubmed: 11437097
Hum Pathol. 2008 Dec;39(12):1809-15
pubmed: 18715613
Science. 1993 Jun 18;260(5115):1805-8
pubmed: 8390097
Cancer Res. 2003 Aug 15;63(16):5028-33
pubmed: 12941830
Nat Med. 2012 Oct;18(10):1511-7
pubmed: 23001183
J Clin Pathol. 2011 Jul;64(7):578-86
pubmed: 21490376
PLoS One. 2012;7(4):e35569
pubmed: 22530051
Oncogene. 2017 Jul 13;36(28):4001-4013
pubmed: 28288136
Mol Cell. 1999 May;3(5):629-38
pubmed: 10360179
Breast Cancer Res Treat. 2016 Dec;160(3):439-446
pubmed: 27744485
Breast Cancer Res. 2018 Jun 14;20(1):53
pubmed: 29898744
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Cell Signal. 2013 Apr;25(4):898-909
pubmed: 23268184
J Immunol. 1993 Sep 1;151(5):2555-61
pubmed: 8360477
Cancer Res. 2014 Dec 1;74(23):6806-19
pubmed: 25252914
Mol Cell Biol. 1998 Jul;18(7):4109-17
pubmed: 9632795
J Bone Miner Res. 2014 Jun;29(6):1492-505
pubmed: 24339143
Calcif Tissue Int. 2010 Mar;86(3):261-70
pubmed: 20157807
Ann Oncol. 2008 Aug;19(8):1379-1386
pubmed: 18487549
Cytokine. 2006 Mar 21;33(6):323-36
pubmed: 16713283
Oncogene. 2014 Mar 20;33(12):1485-94
pubmed: 23584474
Science. 1994 Jan 7;263(5143):92-5
pubmed: 8272873
J Cell Physiol. 1992 Jul;152(1):71-8
pubmed: 1618924
J Pathol. 2019 Sep;249(1):6-18
pubmed: 31095738
J Vis Exp. 2012 Sep 04;(67):e4260
pubmed: 22972196
Clin Exp Metastasis. 2005;22(1):47-59
pubmed: 16132578
Cancer Res. 2008 Aug 1;68(15):6241-50
pubmed: 18676848
Front Immunol. 2019 May 15;10:1093
pubmed: 31156640
EMBO J. 1999 Aug 2;18(15):4261-9
pubmed: 10428964
Mol Oncol. 2014 May;8(3):508-19
pubmed: 24462521
PLoS One. 2011 Apr 26;6(4):e19309
pubmed: 21541295
Cancer Treat Rev. 2001 Jun;27(3):165-76
pubmed: 11417967
PLoS One. 2014 Jan 24;9(1):e86641
pubmed: 24475161
Medicine (Baltimore). 2016 Feb;95(8):e2909
pubmed: 26937933
APMIS. 2012 Jul;120(7):549-57
pubmed: 22716210
J Bone Oncol. 2013 Oct 03;2(4):137-44
pubmed: 26909284
Oncotarget. 2014 Feb 15;5(3):788-801
pubmed: 24553191
Oncotarget. 2019 Mar 12;10(21):2068-2085
pubmed: 31007849
J Transl Med. 2017 May 4;15(1):97
pubmed: 28472954
Pharm Acta Helv. 2000 Mar;74(2-3):265-72
pubmed: 10812968
Sci Rep. 2014 Feb 06;4:4012
pubmed: 24500246
Science. 2003 Jun 27;300(5628):2101-4
pubmed: 12829785
Cancer Res. 2011 Feb 1;71(3):822-31
pubmed: 21189326
Curr Osteoporos Rep. 2011 Jun;9(2):89-95
pubmed: 21424744
PLoS One. 2013 May 21;8(5):e63204
pubmed: 23704896
Breast Cancer Res Treat. 2012 Apr;132(3):1025-34
pubmed: 21773767
J Clin Invest. 1996 Oct 1;98(7):1544-9
pubmed: 8833902
J Biol Chem. 1996 Dec 20;271(51):32635-43
pubmed: 8999038
Trends Cell Biol. 2006 May;16(5):257-63
pubmed: 16581250
Breast Cancer Res Treat. 2013 Jul;140(2):219-32
pubmed: 23836010
Bone. 2002 Jul;31(1):212-9
pubmed: 12110437
Breast Cancer Res Treat. 2009 Dec;118(3):433-41
pubmed: 19052860
Genes Cancer. 2012 Feb;3(2):117-30
pubmed: 23050044
Cancer Cell. 2016 Sep 12;30(3):459-473
pubmed: 27622335

Auteurs

Tolu Omokehinde (T)

Graduate Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA.
Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN, USA.

Alec Jotte (A)

Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
Department of Biochemistry, Vanderbilt University, Nashville, TN, USA.

Rachelle W Johnson (RW)

Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH